The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for AB569 from Arch Biopartners Inc. as a treatment for Pseudomonas aeruginosa (P. aeruginosa) pulmonary infections in patients with cystic fibrosis. The Orphan Drug Designation is a crucial step for the development of new medicines for…
A new study entitled “Lung Microbiota Changes Associated with Chronic Pseudomonas aeruginosa Lung Infection and the Impact of Intravenous Colistimethate Sodium,” published in the PLOS One journal, highlights the potentially positive impact of intravenous antibiotic colistimethate sodium in the proportion of Pseudomonadales relative to other Gram-negative…
A new study entitled “Respiratory microbiota resistance and resilience to pulmonary exacerbation and subsequent antimicrobial intervention,” published in The International Society for Microbial Ecology Journal, investigated how bacterial communities in the lung change over time in relation to the disease state and progression of…
A small study by scientists in Israel indicates that treatment with ivacaftor in people with cystic fibrosis (CF) and a specific gene mutation may help with insulin secretion problems. The study, titled “CFTR potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation,“ appeared in the Nov. 4, 2015,…
A new study entitled “Vitamin D and Chronic Lung Colonization in Pediatric and Young Adult Cystic Fibrosis Patients” published in the Spanish-language journal Nutrición Hospitalaria, investigated vitamin D levels in the body and its association with chronic lung colonization. The study showed that vitamin D supplements did not improve…
A new study revealed that the cystic fibrosis transmembrane conductance regulator (CFTR) plays an important role in regulating the intestinal inflammatory responses. The study, entitled “CFTR Knockdown induces pro inflammatory changes in intestinal epithelial cells,” was published in the Journal of Inflammation…
Scientists at the Center for Nanomedicine at the Wilmer Eye Institute, part of Johns Hopkins University School of Medicine, may have found a new way to track the stages and the progression of cystic fibrosis (CF) by examining mucus in the lungs of CF patients. If so, mucus under a microscope…
A researcher from the Faculty of Medicine, Shiraz University of Medical Sciences, in Iran, has suggested the unconventional idea that people with cystic fibrosis (CF) could be more resilient to cholera and, vice versa, that people who contract cholera could develop resistance to cystic fibrosis. The work, titled “Cystic…
Assistant Professor Sigrid Ladores, PhD, from the School of Nursing, University of Alabama at Birmingham, and doctoral student Leigh Ann Bray are developing a study entitled “Female Fertility in the Age of New CFTR-Modulating Drugs.” The main focus of the research study will be to assess female patients’ understanding of…
A new study revealed that treating P. aeruginosa biofilms with the antibiotic tobramycin together with mannitol — two well-known therapies in treating lung infections in CF — did not reduce overall bacterial load. The study entitled “Mannitol Does Not Enhance Tobramycin Killing of Pseudomonas aeruginosa in a Cystic Fibrosis Model System…
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.
Get regular updates to your inbox.